Lauren Riker - 18 Jan 2022 Form 4 Insider Report for Pacira BioSciences, Inc. (PCRX)

Role: Senior Vice President, Finance
Signature: /s/ Kristen Williams, Attorney-in-Fact
Issuer symbol: PCRX
Transactions as of: 18 Jan 2022
Net transactions value: -$135,405
Form type: 4
Filing time: 20 Jan 2022, 18:22:49 UTC
Previous filing: 10 Jan 2022
Next filing: 14 Mar 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PCRX	Common Stock	Options Exercise	$27,025	+2,500	+16%	$10.81	17,652	18 Jan 2022	Direct	F1
transaction	PCRX	Common Stock	Sale	$162,430	-2,500	-14%	$64.97	15,152	18 Jan 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PCRX	Stock Option (Right to Buy)	Options Exercise	$0	-2,500	-21%	$0.000000	9,300	18 Jan 2022	Common Stock	2,500	$10.81	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
F2	The option vested and became exercisable as to 25% of the option shares on June 5, 2013 and vested as to the remaining shares in successive equal monthly installments for the subsequent 36 months.